Ceryx Medical Initiates Cysoni RSA Pacemaker First-in-Human Study

The first patient has been enrolled in Ceryx’s RSA-Pace multi-center study at Waikato Hospital in Hamilton, New Zealand. The study will evaluate the safety of Cysoni RSA Pacemaker temporary pacing technology in the treatment of post-surgical heart failure patients who require temporary pacing. 

“We would like to thank Dr Stiles and the team at Waikato,” said Dr Stuart Plant, CEO, Ceryx. “We believe that the results from this first-in-human study will help us understand the role of RSA pacing as we strive to develop temporary and permanent pacing devices based on this unique technology. We are exceptionally pleased with the performance of the Cysoni system so far, it’s ability to restore RSA appears to be exceeding our expectations.”

Ceryx’s Cysoni pacing technology is designed to provide superior therapeutic outcomes for Heart Failure patients by improving cardiac output using Respiratory Sinus Arrythmia (RSA) inputs to inform the pacing algorithm.

The RSA-Pace study will enroll up to 60 patients at centers in the UK, New Zealand, and Australia.

“We are delighted to have enrolled the first patient in this important study. The Ceryx Cysoni pre-clinical results have been most impressive and have shown that this technology has the potential to improve cardiac output compared to existing pacing technologies. This is an exciting and novel approach, and we are interested to understand the benefits of RSA pacing in a post-surgical patient population,” said Dr Martin Stiles, Principle Investigator at Waikato Hospital.

The Cysoni pacing technology has proven to increase cardiac output by up to 20%, reduce symptoms of heart failure such as apnoeas, and reverse myocardial damage in a controlled in-vivo study. It can also be used alongside existing therapies.